Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

被引：0
作者：
Michela Del Prete
François-Alexandre Buteau
Jean-Mathieu Beauregard
机构：
[1] Université Laval,Department of Radiology and Nuclear Medicine, and Cancer Research Center
[2] CHU de Québec – Université Laval,Department of Medical Imaging, and Oncology Branch of Research Center
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Personalized; Peptide receptor radionuclide therapy; Lu-octreotate; Dosimetry; Neuroendocrine tumours;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1490 / 1500
页数：10
相关论文
共 50 条
  • [21] Peptide receptor radionuclide therapy of neuroendocrine tumours
    Bodei, L.
    Giammarile, F.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2009, 33 (03): : 142 - 147
  • [22] Peptide receptor radionuclide therapy of neuroendocrine tumours
    Brabander, Tessa
    Teunissen, Jaap J. M.
    Van Eijck, Casper H. J.
    Franssen, Gaston J. H.
    Feelders, Richard A.
    de Herder, Wouter W.
    Kwekkeboom, Dik J.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 30 (01) : 103 - 114
  • [23] Peptide receptor radionuclide therapy for neuroendocrine tumours
    Siraj Yusuf
    Shahad Alsadik
    Adil AL-Nahhas
    Clinical and Translational Imaging, 2018, 6 : 101 - 111
  • [24] Peptide receptor radionuclide therapy for neuroendocrine tumours
    Yusuf, Siraj
    Alsadik, Shahad
    Al-Nahhas, Adil
    CLINICAL AND TRANSLATIONAL IMAGING, 2018, 6 (02) : 101 - 111
  • [25] Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations
    Hou, Xinchi
    Zhao, Wei
    Beauregard, Jean-Mathieu
    Celler, Anna
    PHYSICS IN MEDICINE AND BIOLOGY, 2019, 64 (17)
  • [26] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
  • [27] Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour
    Anna Yordanova
    Karin Mayer
    Peter Brossart
    Maria A. Gonzalez-Carmona
    Christian P. Strassburg
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1207 - 1214
  • [28] Long-term survival and toxicity in patients with neuroendocrine tumors treated with Lu-177-octreotate peptide radionuclide therapy
    Kennedy, Kim R.
    Turner, John Harvey
    MacDonald, William B. G.
    Claringbold, Phillip G.
    Boardman, Glenn
    Ransom, David T.
    CANCER, 2022, 128 (11) : 2182 - 2192
  • [29] Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours
    Tham, W. Y. A.
    Huang, H. L.
    Tai, W. M. D.
    Yan, X. S.
    Ng, C. E. D.
    Loke, S. H. K.
    NEUROENDOCRINOLOGY, 2020, 110 : 275 - 275
  • [30] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Bodei, Lisa
    Cremonesi, Marta
    Grana, Chiara M.
    Fazio, Nicola
    Iodice, Simona
    Baio, Silvia M.
    Bartolomei, Mirco
    Lombardo, Dario
    Ferrari, Mahila E.
    Sansovini, Maddalena
    Chinol, Marco
    Paganelli, Giovanni
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2125 - 2135
12345